Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration
06 déc. 2021 09h15 HE | Atossa Therapeutics, Inc.
SEATTLE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and...